论文部分内容阅读
目的本文主要是为了探讨和分析肺结核合并真菌感染患者的临床表现特征以及耐药性。方法选择2014年3月到2015年3月来我院接受治疗的150例肺结核合并真菌感染的患者临床资料作为研究对象,并对其临床特征和耐药性进行分析和探讨。结果150例肺结核合并真菌感染患者主要以合并下呼吸道真菌感染、糖尿病、低蛋白血症为主,患者大都长期使用糖皮质激素或者广谱抗生素。其中病原菌检测结果显示主要为白色假丝酵母菌,占总人数的72.15%,伊曲康唑、5-氟胞嘧啶以及良性霉素B等药物是对真菌耐药率较低的抗真菌药物。经过系统的治疗之后,共有132例患者的痰菌检测从阳性向阴性转变,其余的18例患者有11例未出现变化、7例死亡,死亡率为4.7%。结论肺结核合并真菌感染患者在临床医学治疗中呈现出逐渐增长的趋势,医务工作人员需要对患者的病变特点、耐药情况进行重视和了解,并在临床治疗过程中采取有效的治疗方案。
Objective This article is mainly to investigate and analyze the clinical manifestations and drug resistance of patients with pulmonary tuberculosis and fungal infection. Methods Clinical data of 150 patients with pulmonary tuberculosis complicated with fungal infection who were treated in our hospital from March 2014 to March 2015 were selected as the research object and their clinical characteristics and drug resistance were analyzed and discussed. Results 150 cases of pulmonary tuberculosis complicated with fungal infection mainly associated with lower respiratory tract fungal infection, diabetes, hypoproteinemia-based, most patients with long-term use of glucocorticoid or broad-spectrum antibiotics. Pathogen test results showed that Candida albicans, accounting for 72.15% of the total number, and itraconazole, 5-fluorocytosine, and benignomycin B and other drugs are fungal antifungal drugs with low resistance rate. After systematic treatment, a total of 132 patients had a change in sputum from positive to negative and the remaining 18 patients had no change in 11 and 7 died, with a 4.7% mortality rate. Conclusions Patients with pulmonary tuberculosis and fungal infection show a trend of gradually increasing in clinical medical treatment. Medical staffs need to pay attention to and understand the characteristics of patients’ lesions and drug resistance, and take effective treatment in clinical treatment.